Mexiletine: Antiarrhythmic mechanisms, emerging clinical applications and mortality
Pacing and Clinical Electrophysiology · 2023
DOI: 10.1111/pace.14846 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pacing and Clinical Electrophysiology, 2023. Verfasst von Farah Olleik und 5 weiteren Autor:innen. Beteiligte Einrichtung: Lankenau Medical Center and Lankenau Institute for Medical Research, Wynnewood, Pennsylvania, USA. Hauptthemen laut MEDLINE: Anti-Arrhythmia Agents, Long QT Syndrome. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 72 Literaturangaben.
Abstract (Originalsprache)
Mexiletine, a class Ib antiarrhythmic drug, exhibits its major antiarrhythmic effect via inhibition of the fast and late Na + currents in myocardial tissues that are dependent on the opening of Na + channels for their excitation. Through a comprehensive examination of mexiletine's therapeutic benefits and potential risks, we aim to provide valuable insights that reinforce its role as a vital therapeutic option for patients with ventricular arrhythmias, long QT syndrome, and other heart rhythm disorders. This review will highlight the current understandings of the antiarrhythmic effects and rationales for recent off‐label use and address the mortality and proarrhythmic effects of mexiletine utilizing published basic and clinical studies over the past five decades.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Lankenau Medical Center and Lankenau Institute for Medical Research, Wynnewood, Pennsylvania, USA.
- Tianjin Key Laboratory of Ion-Molecular Function of Cardiovascular Disease, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin, PR China.
- Kent and Medway Medical School, Canterbury, Kent, UK.
- School of Nursing and Health Studies, Hong Kong Metropolitan University, Hong Kong, PR China.
- Fuwai Huazhong Hospital, Chinese Academy of Medical Sciences, Zhengzhou, PR China.
- Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
ORCID-Profile: Gan-Xin Yan
Zitieren
APA
Olleik, F., Kamareddine, M. H., Spears, J., Tse, G., Liu, T., & Yan, G. X. (2023). Mexiletine: Antiarrhythmic mechanisms, emerging clinical applications and mortality. Pacing and Clinical Electrophysiology. https://doi.org/10.1111/pace.14846
Vancouver
Olleik F, Kamareddine MH, Spears J, Tse G, Liu T, Yan GX. Mexiletine: Antiarrhythmic mechanisms, emerging clinical applications and mortality. Pacing and Clinical Electrophysiology. 2023. doi:10.1111/pace.14846
BibTeX
@article{Olleik2023,
author = {Olleik, Farah and Kamareddine, Mohammed Hussein and Spears, Jenna and Tse, Gary and Liu, Tong and Yan, Gan-Xin},
title = {Mexiletine: Antiarrhythmic mechanisms, emerging clinical applications and mortality},
journal = {Pacing and Clinical Electrophysiology},
year = {2023},
doi = {10.1111/pace.14846}
}
EUVIMED